At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...

Analyst Mani Foroohar of Leerink Partners maintained a Sell rating on Moderna (MRNA – Research Report), reducing the price target to ...

Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance.

In a report released today, Terence Flynn from Morgan Stanley assigned a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...

The meeting is a popular venue for dealmaking and discussions between pharma and biotech companies. Investors are eager to see more of Moderna’s pipeline become approved products. Moderna had ...

The VanEck Biotech ETF (BBH) and iShares Biotechnology ETF (IBB), with significant holdings in Moderna and BioNTech, saw increased buying activity. Broader health care ETFs like the Health Care ...